Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828197) titled 'A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Condition:
Overweight and/or Obesity
Healthy Participants
Intervention:
Drug: HDM1005
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 3, 2026
Target Sample Size: 135
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/...